Delivering Solid Form Solutions with Decades of Expertise – Your Partner for Solid State and Preclinical Formulation Services.
CONTACT
- info@solitekpharma.com
- [+34] 614 65 22 57
- Parc Científic de Barcelona, Carrer de Baldiri Reixac, 10-12 (08028)
Advanced Computational Solid-State Services
Model crystallization processes, use in silico tools to accelerate cocrystal screening, and reduce risks in the development of your API before going into the lab
Advanced Computational Solid State Analysis
Virtual Cocrystal Screening
We combine different computational models to evaluate and prioritize coformers before starting experimental screening.
Crystallization Process Modelling
We integrate solubility, supersaturation, and process variables to explore and better understand the operating space of a crystallization process.
Computational + Experimental
Predictions are not considered a final result. We use them to design more targeted experimental work and generate data that support decision-making.
40+ Years in Solid-State
More than 40 years dedicated to solid-state science, development, and optimization.
Computational Risks in Drug Development
Situations you may be facing or could encounter
Blind spots:
Blind spots: Relying solely on experimental work may leave relevant regions of the solid-form space, potential cocrystals, or critical crystallization process variables unexplored.
Limited API availability:
Consuming significant quantities of a scarce API in broad experimental campaigns, when computational analysis can help prioritize the experiments most likely to provide useful information.
Patent gaps:
ncomplete exploration of the solid-form space may leave intellectual property opportunities unidentified.
Uncertainty in behavior:
An incomplete understanding of how solubility, supersaturation, nucleation, crystal growth, and process variables interact can make it more difficult to develop a robust crystallization process.
Lack of predictability during scale-up:
Developing or scaling up a crystallization process without first modelling the effect of the main process variables can increase the risk of unexpected changes in system behavior during scale-up.
Computational Solutions for Solid State Chemistry
A) Virtual Cocrystal Screening:
Virtual screening of coformers using empirical, semi-empirical, and theoretical models to prioritize candidates with the highest probability of success before experimental screening.
B) Crystallization Process Modelling:
Thermodynamic and kinetic modelling of solubility, supersaturation, and process variables to better understand crystallization behavior, explore the operating space, and support process development and scale-up.
C) Polymorphism Landscape Review:
Assessment of polymorphism risk and previous experimental work to identify potential gaps and define targeted studies where uncertainty is greatest.
Key Benefits of Our Computational Solid-State Services
- Stronger intellectual property protection: Help identify underexplored areas of the solid-form space and new opportunities, including cocrystals, to direct experimental work toward forms with potential IP value.
- Faster, more targeted development: Reduce the number of options that need to be evaluated experimentally by prioritizing candidates and conditions before starting extensive laboratory campaigns.
- More efficient use of API: Minimize material consumption, particularly in early development, by focusing experiments on the most relevant options.
- More robust crystallization development and scale-up: Thermodynamic and kinetic modelling help understand the effect of process variables and identify more robust operating regions.
- Higher probability of success in cocrystal screening: Computational prioritization of coformers focuses experimental screening on candidates with a higher probability of forming relevant cocrystals.
- Better management of polymorphism risk: Analysis of previous work and the solid-form space helps identify potential gaps and determine where additional studies may be required.
Pharma and Biotech Computational Solutions
How we help if you are
An innovative biotech
We maximize the value of early-stage assets by using computational tools to guide solid-form and crystallization process development while minimizing material consumption.
A pharmaceutical company in development
We use computational tools to prioritize new cocrystal options and model crystallization processes, helping develop forms and processes that are better suited to the product requirements.
A leader in generic pharmaceuticals
We evaluate the solid-form and intellectual property landscape to identify potential gaps and prioritize new forms, including cocrystals, through targeted experimental work.
Testimonials from Pharmaceutical Companies That Have Already Put Their Trust in Solitek
About Solitek Pharma
Expert Computational Solid State Laboratory
Solitek Pharma was founded to reduce risk and prevent costly failures in small molecule drug development, drawing on over 50 years of accumulated experience in the pharmaceutical industry, including more than 40 years focused specifically on solid-state science.
Our expertise was built at internationally recognized pharmaceutical companies such as GSK, Johnson Matthey, and Almac, Spanish companies such as Esteve and Medichem, and specialized solid-state teams such as Pharmorphix and Enantia.
We have participated in more than 1,000 drug development programs, giving us the practical perspective needed to approach each project with a clear sense of what truly needs to be accomplished and decided at every stage.
Our current company, Solitek Pharma, was founded in 2021 and is based at the Barcelona Science Park (Parc Científic de Barcelona), a hub for operations and specialized talent in our sector.
We are an agile team of experts who work closely with our clients, integrating as an extension of their development teams. We focus on what’s needed here and now, helping projects advance with lower risk and greater value for future partners.
"The team at Solitek is world-class. Experts in their field and with a customer-focused attitude, they have supported us on multiple solid state projects over the years, consistently delivering both in terms of technical execution and clean project management and reporting”.
Anthony Debono
Head of R&D API – Medichem, SA
"Solitek provided a highly professional and efficient service, supporting the scale-up process with clear communication, technical expertise, and reliable results".
Marta Monjo
Full Professor at Universitat de Les Illes Balears
“Trabajar con Solitek ha sido un placer. El reto técnico al que se enfrentaban era muy complejo y lo resolvieron con optimismo, eficiencia y rapidez. Colaborar con ellos resultó sencillo y ágil. Su conocimiento técnico y su excelente actitud para afrontar y superar desafíos los convierten en un aliado clave para nuestros proyectos en estado sólido y polimorfismo.”
R&D Director
CDMO & Generics Company
‘Efficient, comprehensive, and budget-friendly, Solitek delivered results that exceeded expectations by identifying polymorphs overlooked by another lab. Their expertise gives me peace of mind when outsourcing my projects.’
Wen Chen
Head of CMC at Eccogene, Inc.
Working Together and Strategic Partners
The Value of Experience in Advanced Computational Solid State
Our 3-Step Work Process
Extensive Experience and Cutting-Edge Technology at Your Team's Disposal
Frequently Asked Questions About Computational Solid-State Services
1.- How does computational solid-state analysis complement experimental screening?
It acts as a prioritization and design tool. Computational analysis can reduce the experimental space, select the most relevant candidates or conditions, and design more targeted studies, saving both time and API.
2.- Can computational analysis completely replace physical laboratory experiments?
No. The two work best together. Computational tools can prioritize possibilities and explore different scenarios, which must then be evaluated and validated experimentally.
3.- What input data does Solitek require to start a computational study?
It depends on the type of study. For virtual cocrystal screening, the starting point is the chemical structure of the API and the available physicochemical information.
For crystallization process modelling, we can also incorporate experimental data on solubility, concentration, temperature, and process conditions, which we would normally generate ourselves.
4.- How can computational analysis help identify intellectual property opportunities?
It can help identify underexplored areas of the solid-form space and prioritize new possibilities, including cocrystals.
These hypotheses can then be used to direct the experimental work required to generate and characterize new forms with potential intellectual property value.
5.- How can computational modelling support crystallization process development and scale-up?
Thermodynamic and kinetic modelling can be used to study how solubility, supersaturation, and key process variables affect crystallization behavior. This helps explore the operating space, identify more robust conditions, and design targeted experiments before scale-up.
6.- Can computational results be used to support a regulatory submission?
Yes, when they are appropriately justified and supported by experimental data. Computational results can provide additional.
Computational Solid-State Services for Smarter Drug Development
Discover the crystalline spectrum of your API before conducting wet-lab experiments.
Use computational solid-state tools to accelerate cocrystal screening, model crystallization processes, reduce experimental work, and support better API development decisions.
